3-benzylsalicylaldehyde | 131628-72-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-benzylsalicylaldehyde
• 英文别名: 3-benzyl-2-hydroxybenzaldehyde；3-(phenylmethyl)salicylaldehyde
• CAS: 131628-72-3
• 化学式: C₁₄H₁₂O₂
• mdl: MFCD11868034
• 分子量: 212.248
• InChiKey: KPRWCZKBOOSXCP-UHFFFAOYSA-N

物化性质

• 沸点：
  332.5±30.0 °C(Predicted)
• 密度：
  1.186±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-benzylsalicylaldehyde 在 吡啶 、 三乙基硅烷 、 sodium azide 、 C₁₉H₁₉Cl₃CoNO 、 四(3,5-二(三氟甲基)苯基)硼酸钠 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 丙酮 为溶剂， 反应 24.0h， 生成 4,7-dibenzylbenzo[d]oxazol-2(3H)-one
  参考文献：
  名称：

  钴-硝基插入介导的酰胺基碳重排通过芳烃上的烷基行走

  摘要：

  我们在此公开了使用 2,6-二取代苯基叠氮甲酸酯的 Cp*Co(III)(LX) 催化的酰胺化烷基迁移。在钴-硝基氮向取代的邻位碳插入后，会产生带有季碳的芳鎓阳离子物质，随后的烷基迁移过程被认为是通过不可预见的烷基行走机制发生的。提出了钴催化剂体系的喹啉醇配体，通过作为内部碱促进最终产物释放的重芳构化过程。这种新的机制模式使[1,2]-和[1,4]-烷基重排成为可能，从而允许N-杂环化合物的结构变化。

  DOI：

  10.1021/jacs.1c10138
• 作为产物：
  描述：

  苯甲基苯酚 以56%的产率得到3-benzylsalicylaldehyde
  参考文献：
  名称：

  Substituted indole, benzofuran and benzothiophene derivatives as

  摘要：

  提供的是公式为##STR1##的取代吲哚、苯并呋喃和苯并噻吩，其中X、R.sup.2和R.sup.3在说明书中有描述。这些化合物是5-脂氧合酶抑制剂，可用作抗炎药物。

  公开号：

  US05093351A1

文献信息

• Acidic Rearrangement of (Benzyloxy)chalcones: A Short Synthesis of Chamanetin
  作者：Gustavo Seoane、Gabriel Sagrera

  DOI：10.1055/s-0029-1217064

  日期：——

  Treatment of (benzyloxy)chalcones with trifluoroacetic acid in refluxing chloroform gave several new benzyl(hydroxy)flavanones in high yields and good regioselectivities. By using this procedure, we prepared the natural compound chamanetin in good yield from readily available reagents. benzylation - rearrangements - protecting groups - chamanetin - chalcones

  在回流的氯仿中用三氟乙酸处理（苄氧基）查耳酮以高收率和良好的区域选择性得到了几种新的苄基（羟基）黄酮。通过使用此程序，我们从容易获得的试剂中以高收率制备了天然化合物Chamanetin。 苄基化-重排-保护基-香豆素-查尔酮
• Carboxylate ion dependency in the Cu(II) catalysed asymmetric Henry reaction: Structural characterisation of a tridentate Schiff base complex containing a coordinated carboxylic acid
  作者：Arzu Akıncı、Duygu Barut Celepci、Leman Karadeniz、Neslihan Korkmaz、Muhittin Aygün、Stephen T. Astley

  DOI：10.1002/aoc.3831

  日期：2017.12

  Six tridentate Schiff base ligands containing tertiary butyl or benzyl substituents were prepared from chiral amino alcohols and salicylaldehyde derivatives. The ligands were employed as catalysts for the Cu(II) catalysed asymmetric Henry reaction. It was discovered that when different carboxylate salts were used instead of copper acetate as the Cu(II) salt, significant changes in the enantioselectivity

  由手性氨基醇和水杨醛衍生物制备了六个含有叔丁基或苄基取代基的三齿席夫碱配体。所述配体用作Cu（II）催化的不对称亨利反应的催化剂。发现当使用不同的羧酸盐代替乙酸铜作为Cu（II）盐时，观察到反应的对映选择性的显着变化。将Cu（OAc）2加到由水杨醛和α，α-二苯基叔胺制备的配体中芥子醇导致深绿色晶体的形成。这些晶体的X射线结构分析表明已形成方形平面的单体络合物，而不是预期的二聚体。在该结构中，铜（II）中心键合到三齿ONO配体和乙酸根离子上。席夫碱配体的质子化醇氧与未配位的乙酸氧原子之间存在强氢键。这些结果加在一起表明，当这种类型的铜配合物用作不对称亨利反应的催化剂时，羧酸根阴离子可能是活性中间体的重要部分。
• Therapeutic morpholino-substituted compounds
  申请人：Robertson D. Alan

  公开号：US20050085471A1

  公开（公告）日：2005-04-21

  Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders, neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

  Morpholino取代的吡啶并[3,4-d]吡嗪、喹诺酮和苯并吡喃衍生物抑制磷脂酰肌醇（PI）3-激酶，该酶调节血小板粘附过程。因此，所述化合物具有抗血栓活性，以及其他药物特性。所声称的化合物由公式（I）、（II）和（III）表示。PI 3-激酶产生3-磷酸化的PI第二信使，在血流条件下刺激血小板粘附。由于血小板粘附是形成血栓的必要步骤，这些化合物在此类条件下抑制PI 3-激酶会抑制或预防血栓形成。这些化合物可用于治疗PI 3-激酶依赖性疾病，包括心血管疾病，如冠状动脉闭塞、中风、急性冠状动脉综合征、急性心肌梗死、血管再狭窄、动脉粥样硬化和不稳定性心绞痛；呼吸系统疾病，如哮喘、慢性阻塞性肺疾病（COPD）和支气管炎；炎症性疾病、肿瘤包括胶质瘤、前列腺癌、小细胞肺癌和乳腺癌，以及与白细胞功能紊乱相关的疾病，如自身免疫和炎症性疾病。
• Therapeutic Morpholino-Substituted Compounds
  申请人：Robertson Alan D.

  公开号：US20080206312A1

  公开（公告）日：2008-08-28

  Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

  Morpholino取代的吡啶并[3,4-d]吡嗪、喹诺酮和苯并吡喃衍生物抑制磷脂酰肌醇（PI）3-激酶，一种调节血小板粘附过程的酶。因此，所述化合物具有抗血栓活性以及其他药物性质。所要求的化合物由公式（I）、（II）和（III）表示。PI 3-激酶产生3-磷酸化PI第二信使，在血流条件下刺激血小板粘附。由于血小板粘附是形成血栓的必要步骤，这些化合物在这种条件下抑制PI 3-激酶会抑制或预防血栓形成。这些化合物可用于治疗PI 3-激酶依赖性疾病，包括心血管疾病，如冠状动脉闭塞、中风、急性冠状动脉综合症、急性心肌梗死、血管再狭窄、动脉粥样硬化和不稳定性心绞痛；呼吸系统疾病，如哮喘、慢性阻塞性肺疾病（COPD）和支气管炎；炎症性疾病；肿瘤，包括胶质瘤、前列腺癌、小细胞肺癌和乳腺癌等癌症；以及与白细胞功能紊乱有关的疾病，如自身免疫性和炎症性疾病。
• The use of 2-phenyltetralin derivatives, or heterocyclic analogues, in medicine and pharmaceutical compositions containing them
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0025598A1

  公开（公告）日：1981-03-25

  Known and novel compounds of formula (i) wherein E is a sulphur atom or a NH or CH2 group, J is a nitrogen atom or a CH group, Q is a sulphur atom or a NR3 or CHR3 group, Z is oxygen or sulphur atom or a NR4 or CHR4 group and R' represents four substituents and R2 represents five substituents, provided at least three of E, J, Q, and Z are methylene residues, are active against viruses, especially rhinoviruses. Methods for producing the compounds are described, as are pharmaceutical formulations and methods for administering the compounds to cure or prevent rhinoviral infections.

  已知和新型的式(i)化合物 其中 E 是硫原子或 NH 或 CH2 基团，J 是氮原子或 CH 基团，Q 是硫原子或 NR3 或 CHR3 基团，Z 是氧或硫原子或 NR4 或 CHR4 基团，R'代表四个取代基，R2 代表五个取代基，条件是 E、J、Q 和 Z 中至少有三个是亚甲基残基。本文介绍了生产这些化合物的方法，以及使用这些化合物治疗或预防鼻病毒感染的药物制剂和方法。